Results indicated that high SLC16A3 and PFKP expression in patients with advanced ovarian cancer was associated with poor PFS, and high SLC16A3 expression in patients with poor or moderate differentiation was associated with poor PFS or PPS (Figures 5A, B). The gene discussed is SLC16A3; the disease is ovarian carcinoma.